

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**  
**{CARTON BOX 1 SYRINGE, 7 SYRINGES, 14 SYRINGES.**  
**BULK PACK OF 72 SYRINGES}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Bimeprazol 370 mg/g oral paste

**2. STATEMENT OF ACTIVE SUBSTANCES**

Omeprazole                    370 mg/g

**3. PACKAGE SIZE**

1 x 6.16 g syringe  
7 x 6.16 g syringes  
14 x 6.16 g syringes  
72 x 6.16 g syringes

**4. TARGET SPECIES**

Horses.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Oral use.

**7. WITHDRAWAL PERIODS**

Withdrawal periods:  
Meat and offal: 1 day.  
Milk: Not authorised for use in mares producing milk for human consumption.

**8. EXPIRY DATE**

Exp. {mm/yyyy}  
Once opened use within 28 days.

**9. SPECIAL STORAGE PRECAUTIONS**

Store below 30 °C.  
Replace cap after use.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Bimeda Animal Health Limited

**14. MARKETING AUTHORISATION NUMBERS**

Vm 50146/4043

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING  
UNITS {SYRINGES}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Bimeprazol 370 mg/g oral paste for horses



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Omeprazole                    370 mg/g

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once opened use within 28 days.

## **PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

### **PACKAGE LEAFLET**

#### **1. Name of the veterinary medicinal product**

Bimeprazol 370 mg/g oral paste for horses

#### **2. Composition**

Each gram contains:

##### **Active substance:**

Omeprazole	370 mg
------------	--------

##### **Excipients:**

Yellow iron oxide (E 172)	4 mg
Butylhydroxytoluene	0.5 mg

Smooth homogeneous tan coloured paste.

#### **3. Target species**

Horses.

#### **4. Indications for use**

For treatment and prevention of gastric ulcers in horses.

#### **5. Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

#### **6. Special warnings**

##### Special warnings:

None.

##### Special precautions for safe use in the target species:

This veterinary medicinal product is not recommended for animals under 4 weeks of age or weighing less than 70 kg body weight.

Stress (including high performance training and competition), feeding, management and husbandry practices may be associated with the development of gastric ulceration in horses. Individuals responsible for the well-being of horses should consider reducing the ulcerogenic challenge by modifying husbandry practices to achieve one or more of the following: reduced stress, reduced fasting, increased intake of roughage and access to grazing.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

As this veterinary medicinal product may cause hypersensitivity, avoid direct contact with skin and eyes. Personal protective equipment consisting of protective clothing including impervious gloves should be worn when handling the veterinary medicinal product. Do not eat or drink when handling and administering the veterinary medicinal product. Wash hands or any exposed skin after use. In case of contact with eyes, wash immediately with clean running water, seek medical advice and show the package leaflet or the label to the physician. Persons developing a reaction after contact with the veterinary medicinal product should avoid handling the veterinary medicinal product in future.

Special precautions for the protection of the environment:

Not applicable.

Pregnancy and lactation:

Laboratory studies in rats and rabbits have not produced any evidence of a teratogenic effect.

In the absence of data during pregnancy and lactation, the use of this veterinary medicinal product in pregnant and lactating mares is not recommended.

Interaction with other medicinal products and other forms of interaction:

Omeprazole may delay the elimination of warfarin. No other interaction with medicines routinely used in the treatment of horses is expected, although interaction with drugs metabolised by liver enzymes cannot be excluded.

Overdose:

No undesirable effects related to treatment were observed following daily use for 91 days at omeprazole dosages up to 20 mg/kg in adult horses and in foals older than 2 months.

No undesirable effects related to treatment (in particular no adverse effect on the semen quality or reproductive behaviour) were observed following daily use for 71 days at an omeprazole dosage of 12 mg/kg in breeding stallions.

No undesirable effects related to treatment were observed following daily use for 21 days at an omeprazole dosage of 40 mg/kg in adult horses.

Major incompatibilities:

Not applicable.

## **7. Adverse events**

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## **8. Dosage for each species, routes and method of administration**

Oral use.

Treatment of gastric ulcers: one administration per day during 28 consecutive days at the dose rate of 4 mg omeprazole per kg body weight followed immediately by a dosage regimen of one administration per day during 28 consecutive days at the dose rate of 1 mg omeprazole per kg body weight, to reduce the recurrence of gastric ulcers during treatment.

Should recurrence occur, re-treatment at a dose rate of 4 mg omeprazole per kg body weight is recommended.

Prevention of gastric ulcers: one administration per day at the dose rate of 1 mg omeprazole per kg body weight.

This veterinary medicinal product is effective in horses of various breeds and under different management conditions; foals as young as four weeks of age and weighing over 70 kg; and breeding stallions.

It is recommended to associate the treatment with changes of husbandry and training practices. Please see also section 6 “Special precautions for safe use in target species”.

## **9. Advice on correct administration**

To deliver the veterinary medicinal product at the dose of 4 mg omeprazole/kg, set the syringe plunger to the appropriate dose division for the horse’s weight. Each full dose division on the syringe plunger delivers sufficient omeprazole to treat 100 kg body weight. The contents of one syringe will treat a 575 kg horse at the rate of 4 mg omeprazole per kg body weight.

To deliver the veterinary medicinal product at the dose of 1 mg omeprazole/kg, set the syringe plunger to the dose division equivalent to one quarter the horse’s body weight. At this dose, each full dose division on the syringe plunger will deliver sufficient omeprazole to treat 400 kg body weight. For example, to treat a horse weighing 400 kg, set the plunger to 100 kg.

## **10. Withdrawal periods**

Meat and offal: 1 day.

Milk: Not authorised for use in mares producing milk for human consumption.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

Store below 30 °C.

Replace cap after use.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the container: 28 days.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

## **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 50146/4043

Pack sizes:

Carton box of 1, 7 or 14 syringes.

Bulk pack of 72 syringes.

Not all pack sizes may be marketed.

## **15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

## **16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release:

Bimeda Animal Health Limited

2/3/4 Airton Close

Tallaght

Dublin 24

Ireland

Local representatives and contact details to report suspected adverse reactions:

DUGV UK Ltd  
Union House, 111 New Union St,  
Coventry. CV1 2NT  
United Kingdom  
Tel: 02476 100 696

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**17. Other information**

POM-V

*Gavin Hall*

Approved: 26 March 2026